Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: IDYA stock price vs TECK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TECK's multiple
Needs TECK P/S.
Implied fair value · at IDYA's multiple
Needs Revenue / share.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · TECK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 15.05x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
TECK RESOURCES LIMITED · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
—
Net debt / EBITDA
Leverage against operating earnings
4.97x
11.15x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$5.01B
Total debt
Interest-bearing obligations outstanding
$84.13M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
CLEVELAND-CLIFFS INC.
IDYA vs CLF
Vale S.A.
IDYA vs VALE
FREEPORT-MCMORAN INC
IDYA vs FCX
SOUTHERN COPPER CORP/
IDYA vs SCCO
NEWMONT Corp /DE/
IDYA vs NEM
$16.97B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
